GSK has joined forces with AstraZeneca and Labcyte to combine acoustic liquid dispensing technology with mass spectrometry (MS) for use in high throughput small molecule screening and other drug discovery applications.

Labcyte’s acoustic liquid dispensing uses the energy of sound waves to move minute quantities of liquid with exact precision.

The technology has been enhanced to create an MS-friendly mist of nano-droplets during acoustic mist ionization (AMI) process.

MS is currently used to quantify the amount of drug substance present in screening assays, drug metabolism studies, and safety and efficacy tests.

When used through AMI in high throughput applications, MS has the capability to decrease cost and reduce cycle time in early drug discovery.

With the collaboration of GSK, the three companies have established a consortium to bolster the development of acoustic-MS for high-throughput chemistry analysis, and biochemical and cell-based assays supporting a wide range of drug targets.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
"We have made significant progress in collaboration with AstraZeneca over the past four years with great results."

Labcyte CEO Mark Fischer-Colbrie said: “We have made significant progress in collaboration with AstraZeneca over the past four years with great results.

“This new consortium will help validate new applications and optimise the acoustic-MS technology for both creating new workflows, as well as for fitting into existing drug discovery processes.”

AstraZeneca claims the acoustic liquid dispensing technology to be capable of conducting biochemical screening applications at rates of up to three samples per second.

AstraZeneca discovery sciences and innovative medicines AZ principal scientist Jonathan Wingfield said: “We have proven that Acoustic-MS technology works, and generates vastly reduced assay development times, improved cost savings and fewer false positives.”

Labcyte intends to launch a commercial Acoustic-MS system that would support a range of assays.